ニュース

Targeted Oncology31 分
Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer
The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.